Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

R. Ladenstein, U. Pötschger, A.D.J. Pearson, P. Brock, R. Luksch, V. Castel, I. Yaniv, V. Papadakis, G. Laureys, J. Malis, W. Balwierz, E. Ruud, P. Kogner, H. Schroeder, A.F. de Lacerda, M. Beck-Popovic, P. Bician, M. Garami, T. Trahair, A. CaneteP.F. Ambros, K. Holmes, M. Gaze, G. Schreier, A. Garaventa, G. Vassal, J. Michon, D. Valteau-Couanet

Research output: Contribution to journalArticle

Cite this

Ladenstein, R., Pötschger, U., Pearson, A. D. J., Brock, P., Luksch, R., Castel, V., Yaniv, I., Papadakis, V., Laureys, G., Malis, J., Balwierz, W., Ruud, E., Kogner, P., Schroeder, H., de Lacerda, A. F., Beck-Popovic, M., Bician, P., Garami, M., Trahair, T., ... Valteau-Couanet, D. (2017). Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. The Lancet Oncology, 18(4), 500-514. https://doi.org/10.1016/S1470-2045(17)30070-0